Articles On Kazia Therapeutics (ASX:KZA)

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the stethoscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim interviews Dr James Garner, CEO & Executive...

Kazia has presented at the annual Congress of the European Society for Medical Oncology (ESMO), held in Barcelona.

Results from phase II study of its brain cancer therapeutic GDC-0084 are expected next quarter.

The company is in discussion with clinicians and potential collaborators regarding the strategy for further development of GDC-0084 in glioblastoma.

Sydney-based oncology biotechnology company Kazia Therapeutics, formerly known as Novogen, has been recognised at the 2019 ANZLF Trans-Tasman Innovation and Growth Awards.

The awards are run by the Australian New Zealand Leadership Forum which brings senior businesses and government leaders together to help both nations prosper in the global economy.

Toxicity can be a significant challenge in the treatment of childhood cancer, so it is very encouraging that GDC-0084 appears to have an acceptable tolerability profile.

The report points out Kazia’s accelerated 2023 GDC-0084 approval and maintains its base case 2024 launch scenario with an updated valuation.

The four award winners will be announced at a dinner in Auckland, New Zealand, next Thursday, September 12, presented by NZ Prime Minister Jacinta Arden.

If GDC-0084 is successful in phase-III, the drug will launch into a disease area that has been poorly served by the last two decades of progress in cancer treatment.

Selection of an INN is usually a necessary step before a new drug can be submitted for commercial registration.

Australia has a well-regulated and high-quality health sector, while its medical research and healthcare infrastructure is of world class. Over the years, the health and medical industry in the country has grown at a rapid pace in terms of...

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women.

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) says it has completed recruitment of patients into Part B of its phase 1 clinical study of Cantrixil in ovarian cancer.

Companies and institutions that provide medical assistance and services, manufactures of medical equipment, engage in clinical trials and development of drugs, are part of the healthcare sector. The Australian government makes significant c...

Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084.

Biotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the safety and efficacy of its investigational new drug GDC-0084, after announcing a “state of the art” phase 1 clinical trial to be conducted a...

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.

Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases.

A new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.

The healthcare industry of Australia plays a major role in developing the country’s economy. The healthcare sector witnessed an increase in the demand for health services by Australia’s growing and ageing population. The growth in the indus...